As reported by An et al. [39], USP18, a member of the deubiquitination enzyme family, plays a vital role in the development of NAFLD through inhibiting TAK1 activation and subsequently restraining the downstream JNK/NF-κB signaling pathways. Here, USP18 is linked to metabolic dysfunction-associated steatotic liver disease.